Gachon University Gil Medical Center

Gachon University Gil Medical Center

Item
http://www.wikidata.org/entity/Q30253976
Long-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisLUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungSequential Compression Device on Body TemperatureIntubation Time With Low Dose RocuroniumA Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisA Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisThe Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsThe Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk SubjectsEfficacy and Safety of Atacicept in Systemic Lupus ErythematosusWeekly Docetaxel Plus Cisplatin or Oxaliplatin for AGCSecond-Line Irinotecan vs. ILF for AGCTopotecan for Irinotecan-Refractory SCLCPost Marketing Surveillance to Observe Safety and Effectiveness of CABOMETYX™ in Korea.Development of a New Immunochemistry Method Using Antibodies of Proteins Related Bile Duct CancerRegulatory Request NIS in KoreaExploring the Efficacy and Safety of Herbal Medicine on Korean Obese Women With or Without Metabolic Syndrome Risk FactorsAvelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line TreatmentA Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or CeritinibAnagre Cap. in Patients With High-Risk Essential ThrombocythemiaAn Open-Label, Long-Term Study of Oral Treprostinil in Subjects With Pulmonary Arterial HypertensionTrial of the Early Combination of Oral Treprostinil With Background Oral Monotherapy in Subjects With Pulmonary Arterial HypertensionLUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCKD-828 Telmisartan Non-Responder TrialAprepitant for Postoperative Nausea and Vomiting in Laparoscopic HysterectomyEfficacy and Safety Study of SHP647 as Maintenance Treatment in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 307)An Efficacy Study Comparing Brigatinib Versus Alectinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Participants Who Have Progressed on CrizotinibM7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Patients With SchizophreniaEvaluation of the Optimal MTX Dose as an Add-on Therapy to Adalimumab for RA Patients in Japan, South Korea and TaiwanEfficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306)Residual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic StrokeA Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene AberrationsDS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]Tesetaxel Plus Reduced Dose of Capecitabine vs. Capecitabine in HER2 Negative, HR Positive, LA/MBCA Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast CancerA Study of Baricitinib (LY3009104) in Combination With Topical Corticosteroids in Adults With Moderate to Severe Atopic DermatitisA Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast CancerA Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer (FIGHT)A Study of Baricitinib in Participants With Systemic Lupus Erythematosus
P6153
Body Composition Monitor in Hemodialysis PatientsSequential Compression Device on Body TemperatureIntubation Time With Low Dose RocuroniumLaryngeal Mask Airway (LMA) Insertion With Sevoflurane and RemifentanilWeekly Docetaxel Plus Cisplatin or Oxaliplatin for AGCSecond-Line Irinotecan vs. ILF for AGCTopotecan for Irinotecan-Refractory SCLCAvelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line TreatmentEffects of Atorvastatin on Adiponectin Levels and Insulin Sensitivity In Hypercholesterolemic PatientsEffects of Fenofibrate on Adipocytokine Levels In Hypertriglyceridemic PatientsAdditive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of HypertensionChanges of Body Temperature During Shoulder ArthroscopyThe Effect of Positive End Expiratory Pressure (PEEP) During Laparoscopic CholecystectomyAprepitant for Postoperative Nausea and Vomiting in Laparoscopic HysterectomyA Trial on Laparoscopic Appendectomy Versus Single Port AppendectomyResidual Shunt After Patent Foramen Ovale Device Closure in Patients With Cryptogenic StrokeThe PAH Platform for Deep Phenotyping in Korean Subjects
P859
Q39185160-11C8BD64-4971-48A6-9E90-4F4E8B5A4743Q39715328-A56C64A5-9633-49DD-A695-B501B9032CD8Q40606527-F0DA5A3B-1AE9-4C80-8251-355E43CF4DD0Q42318039-2F295534-BAF6-4A4E-92C3-9B97C5C43D92Q42429930-899D073D-C9E4-448D-AED4-24BAB6832D4FQ44460364-2A6C0EBC-885F-411E-A2A0-3CB0A349605BQ47143339-DF51557F-06C9-4627-9A91-E6640DF563FAQ51288818-2F4FA3CA-8891-48D4-B11A-CEBEE60B5ADAQ57085464-11709119-3B37-4BDC-9F48-18FB5AA980A7Q57123921-DEA7416D-03B4-4383-85B1-5405162DAEA3Q57413367-591FA789-A8A8-48E8-ADF4-25115EC737CBQ57840679-50147717-79F1-470D-BDF3-A574A7A35C59Q58226436-CDB813F8-87A9-4D49-96E0-E2AE40A5A1D0Q58891017-7674AA33-15EA-42C2-BEED-8B3D60E5BCB8Q59546716-6722D694-EE1E-415D-BDAD-3DFB2E6E1A31Q59682798-7998A1D1-9299-4F08-8C55-BFDED642359AQ59694403-34DBF252-2553-4764-9764-2ED37A7EEBA5Q59831039-D3D9F7C9-895C-406C-8FC0-4EE76155A239Q61160661-96EFBF5E-50ED-462E-BB3E-6B97E0324F1BQ61160667-8459015E-E0D1-4840-9138-F15FD2B2DB53Q62633734-D2547673-BDD8-4212-9999-843235E17C39Q70498275-291A1E76-B79A-4D7F-92B7-0D3A9BB61537Q81399809-240802B2-9852-4A3D-B206-E2F251F49A64Q82524475-4AD05D1A-06B3-4C88-8E78-8BE1598F218EQ84403469-79B5AE81-C2B2-4223-9D05-358EEC5FFC28Q86088174-4BEFCE0E-D142-4A6E-8597-639C7FACB0ABQ86608527-0D349918-6321-4EF0-B248-5ABD0F4E913CQ86829065-871FFC6E-3DDB-4EC4-8E2F-A4EB05E7EEB3Q86937331-8B1FDAE9-A5D5-4DC3-A217-AE4E5C8A6BA5Q87073980-D3BFF19A-285B-426A-8FF6-076EC21B72C6Q87646670-621AE46D-905B-4058-9C19-41EAE2A3BDEDQ87697529-D60605CB-BAC3-449C-858A-97AAE9866474Q88060838-A402CBED-1025-41C7-A396-DDEE15A10066Q88060841-A89B48C2-A6C7-4622-BADD-45F5C02C264CQ88434521-019A9BCB-1F0E-4134-B22A-0AB960FC6C18Q88434521-52449C8E-3C51-44EF-BEF1-A46FCF1ADB4AQ88451819-15D2D1C3-132D-4055-9722-CEB2C16B7D95Q88496654-DA15C7DD-4E10-4BBD-894F-B724F709A15DQ89041433-00690509-C969-41BE-881F-C17B50A4B697Q89104571-A40F245A-BA20-4C48-868B-F7CD67F5B9F2
P108
Q61955644-435DE44D-3CFA-41FA-9570-A42F7E7E1B87Q61956292-48550EA2-BD25-43D4-9C50-2FFE79DEB599Q61956638-A4BE7A22-3F37-44B0-A030-1C7763EADC55Q61956720-6FEC0193-4009-4E27-9EA9-EC18C9E44AC1Q61965830-787135C2-2FBB-44B4-8DA2-11F0661738CAQ61965863-1BD45E75-D79F-4E7A-8F79-4801FC18C3E6Q61974962-AF1CE944-C4D2-444A-9E9F-68D44408C556Q61974963-E465DC53-4B8B-4B64-ABB6-29F9829CF15AQ61975190-90F511A5-0CE2-4428-A14B-46FB2DA32EAAQ61979289-1D6A21D3-88EF-4F47-AB52-B6D2582D4606Q61979316-16F37C5B-9873-4540-8EC3-693C62F6CBDFQ61980222-F93A352C-0EA6-47E3-94F5-927769F52784Q62030840-D76817D2-B266-4E6D-9CDF-DDF38921B481Q62042489-D044303A-4A0A-471D-9405-AC2C1F072917Q62062765-BB97F00E-9C21-4069-AB22-A1CE0499E9B9Q62811874-B6B57949-263C-467D-A3A2-D08745599696Q62813868-451C2DC0-14B8-4E03-96D9-1220356A6C8EQ62814391-73F6E8E7-2F94-42D4-925E-8A4912AE1BDCQ63012207-49152D5D-2F7E-46FA-A2E8-97DD8786C267Q63316626-135F9CDD-200A-4600-9DC6-85BEC7D93B91Q63316631-6BD5E353-F70A-4B14-8CE3-D3A7E8893717Q63319514-B7AC4E89-C2E3-4F4B-AD74-EEA79DA4EDF1Q63321217-F007A8E8-21BF-44A9-89CA-4C4EC1FDBD03Q63322457-A9337AFA-1B3D-440A-8EFD-323953016A8CQ63393569-4DF12F9F-84FC-41D8-B032-09FF7287FE9FQ63394461-57AF8FED-8B03-4EBA-8A99-B8E1F8638835Q63394793-7D20F684-37B3-455D-B995-D0F4B74E15C1Q63395042-B8718130-B2FC-496F-A3CB-A506E1FA633EQ63397885-D780967A-25BF-4389-BF3E-60C613FD442FQ63398075-86E6FFD4-EE20-4A32-8F59-61072D007D21Q63404801-697C15C2-B725-46F7-B5EB-85A8AAC97597Q63405227-780E2EC3-5D4B-4F73-B28F-73E4D14E8C8BQ63533943-D1B2F643-6CEC-4182-A79B-5A0697ABD001Q63534256-1D1C5CF1-27D2-4251-BB65-C4DF6102E8B3Q63572233-0EA0CE26-9F09-46BA-BEC0-E63EA5D703C7Q63572991-5E0DEFCD-A8FD-46F9-B144-174608F11372Q63573252-8B99F1C7-C350-449F-868C-2260EA52084DQ63573361-431E3407-5E67-4D9B-9220-D942ECD59750Q63573590-E1821881-5603-4187-8BB9-7C6D87BCDCCEQ63573814-F9EF49ED-766A-4C03-8D25-9FCC3DE3581D
P6153

Gachon University Gil Medical Center

Item
http://www.wikidata.org/entity/Q30253976
description
healthcare organization in Incheon, South Korea
@en
name
Gachon University Gil Medical Center
@en
type
label
Gachon University Gil Medical Center
@en
prefLabel
Gachon University Gil Medical Center
@en
P131
P17
P213
P2427
P31
P3153
P3500
P571
P625
P6782
P856
P3153
P131
P17
P213
P2427
P31
P3153
P3500
P571
P625
P6782
P856